Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Biosci ; 492024.
Article in English | MEDLINE | ID: mdl-38920106

ABSTRACT

Noradrenaline (NA) and serotonin (5-HT) induce nociception and antinociception. This antagonistic effect can be explained by the dose and type of activated receptors. We investigated the existence of synergism between the noradrenergic and serotonergic systems during peripheral antinociception. The paw pressure test was performed in mice that had increased sensitivity by intraplantar injection of prostaglandin E2 (PGE2). Noradrenaline (80 ng) administered intraplantarly induced an antinociceptive effect, that was reversed by the administration of selective antagonists of serotoninergic receptors 5-HT1B isamoltan, 5-HT1D BRL15572, 5-HT2A ketanserin, 5-HT3 ondansetron, but not by selective receptor antagonist 5-HT7 SB-269970. The administration of escitalopram, a serotonin reuptake inhibitor, potentiated the antinociceptive effect at a submaximal dose of NA. These results, indicate the existence of synergism between the noradrenergic and serotonergic systems in peripheral antinociception in mice.


Subject(s)
Norepinephrine , Receptors, Serotonin , Serotonin Antagonists , Serotonin , Animals , Mice , Norepinephrine/metabolism , Serotonin/metabolism , Serotonin Antagonists/pharmacology , Male , Receptors, Serotonin/metabolism , Dinoprostone/metabolism , Citalopram/pharmacology , Nociception/drug effects , Analgesics/pharmacology , Ondansetron/pharmacology , Ketanserin/pharmacology , Pain/drug therapy , Pain/metabolism , Selective Serotonin Reuptake Inhibitors/pharmacology
2.
Toxicol Appl Pharmacol ; 369: 30-38, 2019 04 15.
Article in English | MEDLINE | ID: mdl-30763598

ABSTRACT

Despite all the development of modern medicine, around 100 compounds derived from natural products were undergoing clinical trials only at the end of 2013. Among these natural substances in clinical trials, we found the resveratrol (RES), a pharmacological multi-target drug. RES analgesic properties have been demonstrated, although the bases of these mechanisms have not been fully elucidated. The aim of this study was to evaluate the involvement of opioid and cannabinoid systems in RES-induced peripheral antinociception. Paw withdrawal method was used and hyperalgesia was induced by carrageenan (200 µg/paw). All drugs were given by intraplantar injection in male Swiss mice (n = 5). RES (100 µg/paw) administered in the right hind paw induced local antinociception that was antagonized by naloxone, non-selective opioid receptor antagonist, and clocinnamox, µOR selective antagonist. Naltrindole and nor-binaltorfimine, selective antagonists for δOR and kOR, respectively, did not reverse RES-induced peripheral antinociception. CB1R antagonist AM251, but not CB2R antagonist AM630, antagonized RES-induced peripheral antinociception. Peripheral antinociception of RES intermediate-dose (50 µg/paw) was increased by: (i) bestatin, inhibitor of endogenous opioid degradation involved-enzymes; (ii) MAFP, inhibitor of anandamide amidase; (iii) JZL184, inhibitor of 2-arachidonoylglycerol degradation involved-enzyme; (iv) VDM11, endocannabinoid reuptake inhibitor. Acute and peripheral administration of RES failed to affect the amount of µOR, CB1R and CB2R. Experimental data suggest that RES induces peripheral antinociception through µOR and CB1R activation by endogenous opioid and endocannabinoid releasing.


Subject(s)
Analgesics/pharmacology , Endocannabinoids/metabolism , Hyperalgesia/prevention & control , Nociceptive Pain/prevention & control , Opioid Peptides/metabolism , Receptor, Cannabinoid, CB1/agonists , Receptors, Opioid, mu/agonists , Resveratrol/pharmacology , Animals , Behavior, Animal/drug effects , Cannabinoid Receptor Antagonists/pharmacology , Carrageenan , Disease Models, Animal , Hyperalgesia/chemically induced , Hyperalgesia/metabolism , Hyperalgesia/psychology , Male , Mice , Narcotic Antagonists/pharmacology , Nociceptive Pain/chemically induced , Nociceptive Pain/metabolism , Nociceptive Pain/psychology , Receptor, Cannabinoid, CB1/metabolism , Receptors, Opioid, mu/metabolism , Signal Transduction
3.
Planta Med ; 83(3-04): 261-267, 2017 Feb.
Article in English | MEDLINE | ID: mdl-27574895

ABSTRACT

Peltatoside is a natural compound isolated from leaves of Annona crassiflora Mart., a plant widely used in folk medicine. This substance is an analogue of quercetin, a flavonoid extensively studied because of its diverse biological activities, including analgesic effects. Besides, a previous study suggested, by computer structure analyses, a possible quercetin-CB1 cannabinoid receptor interaction. Thus, the aim of this work was to assess the antinociceptive effect of peltatoside and analyze the cannabinoid system involvement in this action. The mouse paw pressure test was used and hyperalgesia was induced by intraplantar injection of carrageenan (200 µg/paw). All used drugs were administered by intraplantar administration in Swiss male mice (n = 6). Peltatoside (100 µg/paw) elicited a local inhibition of hyperalgesia. The peripheral antinociceptive action of peltatoside was antagonized by the CB1 cannabinoid antagonist AM251 (160 µg/paw), but not by CB2 cannabinoid antagonist AM630 (100 µg/paw). In order to assess the role of endocannabinoids in this peripheral antinociceptive effect, we used (i) [5Z,8Z,11Z,14Z]-5,8,11,14-eicosatetraenyl-methyl ester phosphonofluoridic acid, an inhibitor of anandamide amidase; (ii) JZL184, an inhibitor for monoacylglycerol lipase, the primary enzyme responsible for degrading the endocannabinoid 2-arachidonoylglycerol; and (iii) VDM11, an endocannabinoid reuptake inhibitor. MAFP, JZL184, and VDM11 did not induce antinociception, respectively, at the doses 0.5, 3.8, and 2.5 µg/paw, however, these three drugs were able to potentiate the peripheral antinociceptive effect of peltatoside at an intermediary dose (50 µg/paw). Our results suggest that this natural substance is capable of inducing analgesia through the activation of peripheral CB1 receptors, involving endocannabinoids in this process.


Subject(s)
Analgesics/pharmacology , Cannabinoids/metabolism , Glycosides/pharmacology , Quercetin/analogs & derivatives , Amidohydrolases/metabolism , Analgesics/chemistry , Analgesics/isolation & purification , Animals , Annona/chemistry , Benzodioxoles/administration & dosage , Benzodioxoles/pharmacology , Cannabinoid Receptor Antagonists/pharmacology , Carrageenan/antagonists & inhibitors , Carrageenan/pharmacology , Dose-Response Relationship, Drug , Endocannabinoids/metabolism , Glycosides/antagonists & inhibitors , Glycosides/chemistry , Glycosides/isolation & purification , Hyperalgesia/drug therapy , Male , Mice , Monoacylglycerol Lipases/drug effects , Pain Measurement/drug effects , Piperidines/administration & dosage , Piperidines/pharmacology , Plant Extracts/pharmacology , Pyrazoles/pharmacology , Quercetin/antagonists & inhibitors , Quercetin/chemistry , Quercetin/isolation & purification , Quercetin/pharmacology , Receptor, Cannabinoid, CB1/antagonists & inhibitors , Receptor, Cannabinoid, CB1/metabolism , Receptor, Cannabinoid, CB2/antagonists & inhibitors , Receptor, Cannabinoid, CB2/metabolism
4.
J Ethnopharmacol ; 151(1): 722-8, 2014.
Article in English | MEDLINE | ID: mdl-24309496

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Pyrostegia venusta is used in traditional Brazilian medicine as a general tonic to treat any inflammatory disease. Several studies have demonstrated that medicinal plants constitute a therapeutic approach for the treatment of obesity-related metabolic and inflammatory disarrangement. Accordingly, we investigated the effects of hydroethanolic extract of Pyrostegia venusta flowers (PvHE) supplementation for the treatment of inflammatory and metabolic dysfunction induced by high-refined-carbohydrate (HC) diet. MATERIAL AND METHODS: The BALB/c mice were fed chow or HC diet for 8 weeks. Part of these animals was fed with HC diet supplemented with PvHE on the 9th week until the 12th week. At the end of the dietary intervention, animals were sacrificed. RESULTS: We observed that PvHE decreased adiposity and adipocyte area; improved glucose intolerance; reduced serum triacylglycerol levels and systemic inflammatory cells; and also reduced some inflammatory mediators levels in adipose tissue and liver. CONCLUSION: The results showed that PvHE has beneficial effects and may treat inflammatory and metabolic dysfunction induced by HC diet, that are associated to a negative modulation of the inflammatory process at systemic and local levels.


Subject(s)
Bignoniaceae/chemistry , Dietary Carbohydrates/adverse effects , Inflammation/drug therapy , Plant Extracts/pharmacology , Animals , Dietary Carbohydrates/administration & dosage , Female , Glucose Tolerance Test , Mice , Mice, Inbred BALB C , Plant Extracts/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...